|
US5700913A
(en)
|
1982-12-15 |
1997-12-23 |
Ajinomoto Co., Inc. |
Unglycosylated human interleukin-2 polypeptides
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
PT83761B
(pt)
|
1985-11-19 |
1989-06-30 |
Schering Biotech Corp |
Metodo para a producao de interleuquina-4 de mamifero
|
|
US6028186A
(en)
|
1991-06-10 |
2000-02-22 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands of cytokines
|
|
US5795966A
(en)
|
1995-02-22 |
1998-08-18 |
Immunex Corp |
Antagonists of interleukin-15
|
|
US7008624B1
(en)
|
1995-02-22 |
2006-03-07 |
Immunex Corporation |
Antagonists of interleukin-15
|
|
US5908839A
(en)
|
1995-08-24 |
1999-06-01 |
Magainin Pharmaceuticals, Inc. |
Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
|
|
IL130238A0
(en)
|
1999-06-01 |
2000-06-01 |
Peptor Ltd |
Conformationally constrained backbone cyclized interleukin-6 antagonists
|
|
AU2937597A
(en)
|
1996-05-10 |
1997-12-05 |
Biogen, Inc. |
Common gamma chain blocking agents
|
|
US6127387A
(en)
|
1996-12-10 |
2000-10-03 |
Thomas Jefferson University |
Use of CD4-binding small molecules to inhibit immune responses
|
|
ATE375363T1
(de)
|
1997-07-14 |
2007-10-15 |
Bolder Biotechnology Inc |
Derivate des wachstumshormons und verwandte proteine
|
|
US7189400B2
(en)
|
1998-03-17 |
2007-03-13 |
Genetics Institute, Llc |
Methods of treatment with antagonists of MU-1
|
|
US7198789B2
(en)
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
|
US6861227B2
(en)
|
1998-03-19 |
2005-03-01 |
Human Genome Sciences, Inc. |
Antibodies to cytokine receptor common gamma chain like
|
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
|
EP0972780A1
(en)
|
1998-05-18 |
2000-01-19 |
Applied Research Systems ARS Holding N.V. |
Il-6 antagonist peptides
|
|
US6307024B1
(en)
|
1999-03-09 |
2001-10-23 |
Zymogenetics, Inc. |
Cytokine zalpha11 Ligand
|
|
US7192713B1
(en)
|
1999-05-18 |
2007-03-20 |
President And Fellows Of Harvard College |
Stabilized compounds having secondary structure motifs
|
|
EP1284747A2
(en)
|
2000-05-12 |
2003-02-26 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for achieving immune suppression
|
|
MXPA03002278A
(es)
|
2000-09-14 |
2004-12-03 |
Beth Israel Hospital |
Modulacion de respuestas de la celula t mediadas por il-2 e il-15.
|
|
CA2425506A1
(en)
|
2000-10-18 |
2002-08-01 |
Immunex Corporation |
Methods for treating rheumatoid arthritis using il-17 antagonists
|
|
US20040126900A1
(en)
|
2001-04-13 |
2004-07-01 |
Barry Stephen E |
High affinity peptide- containing nanoparticles
|
|
EP1406700A1
(en)
|
2001-07-06 |
2004-04-14 |
Sucampo AG |
Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
|
|
AU2002356858A1
(en)
|
2001-10-24 |
2003-05-06 |
National Jewish Medical And Research Center |
Structure of tall-1 and its cognate receptor
|
|
EP2130919A1
(en)
|
2001-11-05 |
2009-12-09 |
ZymoGenetics, Inc. |
IL-21 antagonists
|
|
WO2004003140A2
(en)
|
2002-01-18 |
2004-01-08 |
Zymogenetics, Inc. |
Cytokine receptor zcytor17 multimers
|
|
CA2481304A1
(en)
|
2002-03-27 |
2003-10-09 |
Patrick Hwu |
Method for treating cancer in humans
|
|
AU2003230834A1
(en)
|
2002-04-09 |
2003-10-27 |
Beth Israel Deaconess Medical Center, Inc. |
Antagonists of il-21 and modulation of il-21-mediated t cell responses
|
|
WO2003092610A2
(en)
|
2002-05-01 |
2003-11-13 |
Regeneron Pharmaceuticals, Inc. |
Methods of using cytokine antagonists to treat hiv infection and aids
|
|
MXPA04012116A
(es)
|
2002-06-07 |
2005-04-19 |
Zymogenetics Inc |
Uso del il-21 en cancer y otras aplicaciones terapeuticas.
|
|
CA2490804C
(en)
|
2002-06-28 |
2016-12-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
|
|
WO2004003156A2
(en)
|
2002-07-01 |
2004-01-08 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Il-21 as a regulator of immunoglobin production
|
|
MXPA05000655A
(es)
|
2002-07-15 |
2006-02-22 |
Harvard College |
Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
|
|
KR20050049545A
(ko)
|
2002-10-14 |
2005-05-25 |
에프. 호프만-라 로슈 아게 |
길항제 ｉｌ-15
|
|
EP1444989A1
(en)
|
2003-02-07 |
2004-08-11 |
Giorgio Dr. Stassi |
Sensitizing cells for apoptosis by selectively blocking cytokines
|
|
RU2005132458A
(ru)
|
2003-03-21 |
2006-03-20 |
Уайт (Us) |
Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21
|
|
WO2004103295A2
(en)
|
2003-05-14 |
2004-12-02 |
Bayer Pharmaceuticals Corporation |
Interleukin-9 antagonist muteins and their pharmacological methods of use
|
|
CA2529520A1
(en)
|
2003-06-19 |
2004-12-29 |
Centocor, Inc. |
Interleukin-21 analogs
|
|
ES2356154T3
(es)
|
2003-07-21 |
2011-04-05 |
Transgene S.A. |
Citoquinas multifuncionales.
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US7785580B2
(en)
|
2003-08-29 |
2010-08-31 |
Aerovance, Inc. |
Modified IL-4 mutein receptor antagonists
|
|
US7276478B2
(en)
|
2003-09-25 |
2007-10-02 |
Zymogenetics, Inc. |
Methods of treating autoimmune diseases using IL-21
|
|
US20060228331A1
(en)
|
2003-10-10 |
2006-10-12 |
Novo Nordisk A/S |
IL-21 Derivatives and variants
|
|
WO2005067956A2
(en)
|
2004-01-15 |
2005-07-28 |
Novo Nordisk A/S |
Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection
|
|
EP1751175B1
(en)
|
2004-05-05 |
2012-07-25 |
VALORISATION-RECHERCHE, Société en Commandite |
Interleukin-1 receptor antagonists, compositions, and methods of treatment
|
|
EP1753458A4
(en)
|
2004-05-19 |
2009-07-22 |
Wyeth Corp |
MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
|
|
MX2007001509A
(es)
|
2004-08-05 |
2007-03-27 |
Wyeth Corp |
Antagonismo de la actividad del receptor de interleuquina 21.
|
|
CU23472A1
(es)
|
2004-09-17 |
2009-12-17 |
Ct Ingenieria Genetica Biotech |
Péptido antagonista de la interleucina-15
|
|
WO2006105538A2
(en)
|
2005-03-31 |
2006-10-05 |
Centocor, Inc. |
Methods and compositions for treating il-21 related pathologies
|
|
GT200600148A
(es)
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
|
AU2006237329B2
(en)
|
2005-04-18 |
2012-04-12 |
Novo Nordisk A/S |
IL-21 variants
|
|
WO2007001677A2
(en)
|
2005-05-17 |
2007-01-04 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
US20070122413A1
(en)
|
2005-11-28 |
2007-05-31 |
Sivakumar Pallavur V |
Il-21 antagonists
|
|
EP2066689A4
(en)
|
2006-09-07 |
2010-04-28 |
Univ South Florida |
HYD1-PEPTIDE AS ANTICREMENT
|
|
AU2007310777A1
(en)
|
2006-10-26 |
2008-05-02 |
Novo Nordisk A/S |
IL-21 variants
|
|
EP2109620B1
(en)
*
|
2006-12-21 |
2012-08-22 |
Novo Nordisk A/S |
Interleukin-21 variants with altered binding to the il-21 receptor
|
|
US7910123B2
(en)
|
2007-09-05 |
2011-03-22 |
Warsaw Orthopedic |
Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent
|
|
WO2009100035A2
(en)
|
2008-02-01 |
2009-08-13 |
Wyeth |
Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
|
|
US8513208B2
(en)
|
2008-02-28 |
2013-08-20 |
Argos Therapeutics, Inc. |
Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
|
|
WO2009132821A1
(en)
|
2008-04-28 |
2009-11-05 |
Giuliani International Limited |
Interleukin (il-21) binding proteins and methods of making and using same
|
|
US20110091515A1
(en)
|
2008-06-12 |
2011-04-21 |
Ramot At Tel-Aviv University Ltd. |
Drug-eluting medical devices
|
|
EP2356139A4
(en)
|
2008-07-23 |
2013-01-09 |
Harvard College |
LIGURE COMBINED POLYPEPTIDES
|
|
WO2010039533A2
(en)
|
2008-09-23 |
2010-04-08 |
Wyeth |
Methods for predicting production of activating signals by cross-linked binding proteins
|
|
AU2009316076B2
(en)
|
2008-11-17 |
2015-11-19 |
Kobenhavns Universitet |
IL-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
|
|
JP2012514586A
(ja)
|
2009-01-05 |
2012-06-28 |
フラウンホーファーゲゼルシャフト ツール フォルデルング デル アンゲヴァンテン フォルシユング エー．フアー． |
Ｉｌ−２１およびｉｌ−２１変異体に基づく抗体欠乏性疾患を治療するための手段および方法
|
|
NZ594514A
(en)
|
2009-03-05 |
2013-06-28 |
Abbott Lab |
Interleukin-17 BINDING PROTEINS
|
|
US20120107267A1
(en)
|
2009-03-11 |
2012-05-03 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
|
GB0908613D0
(en)
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
|
WO2011008260A2
(en)
|
2009-07-13 |
2011-01-20 |
President And Fellows Of Harvard College |
Bifunctional stapled polypeptides and uses thereof
|
|
CN102753574B
(zh)
|
2009-12-11 |
2015-05-20 |
西马生物医学计划公司 |
用于免疫治疗和抗肿瘤治疗的缀合物和组合物
|
|
US9028797B2
(en)
|
2010-02-26 |
2015-05-12 |
Nagasaki University |
Composite body for antigen or drug delivery
|
|
CA2797033C
(en)
|
2010-04-22 |
2021-10-19 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
|
EP2580238A1
(en)
|
2010-06-09 |
2013-04-17 |
Zymogenetics, Inc. |
Dimeric vstm3 fusion proteins and related compositions and methods
|
|
WO2012006585A2
(en)
|
2010-07-09 |
2012-01-12 |
The Regents Of The University Of California |
Use of interleukin-15 to treat cardiovascular diseases
|
|
US20130224109A1
(en)
|
2010-07-20 |
2013-08-29 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods featuring il-6 and il-21 antagonists
|
|
CA2824515C
(en)
|
2011-01-18 |
2022-09-13 |
Bioniz, Llc |
Compositions and methods for modulating gamma-c-cytokine activity
|
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
|
US9959384B2
(en)
|
2013-12-10 |
2018-05-01 |
Bioniz, Llc |
Methods of developing selective peptide antagonists
|
|
US10858452B2
(en)
*
|
2015-09-16 |
2020-12-08 |
Insitut National de la Sante et de la Recherche Medicale (INSERM) |
Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
|
|
EP3978512A1
(en)
|
2015-10-09 |
2022-04-06 |
Bioniz, LLC |
Modulating gamma-c-cytokine activity
|
|
EP3538548A4
(en)
*
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
KR102707650B1
(ko)
|
2017-04-07 |
2024-09-19 |
바이오니즈 테라퓨틱스, 아이엔씨. |
감마-c-사이토카인 활성의 안정한 조절자
|
|
KR20260042328A
(ko)
|
2020-06-24 |
2026-03-31 |
바이오니즈 테라퓨틱스, 아이엔씨. |
사이토카인 방출 증후군 및 사이토카인 폭풍 관련 장애의 치료를 위한 IL-2, IL-9 및 IL-15 신호 전달을 표적으로 하는 길항 펩티드(ANTAGONISTIC PEPTIDE TARGETING IL-2, IL-9, AND IL-15 signaling for the Treatment of CYTOKINE-RELEASE SYNDROME AND CYTOKINE STORM associated disorders)
|